DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN ISRAEL ONLY.
Information about the Nuvaxovid JN.1 dispersion for injection COVID‑19 Vaccine (recombinant, adjuvanted)
Novavax's COVID-19 vaccine Nuvaxovid JN.1 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) has been granted an import and use permit for active immunization to prevent COVID-19 in individuals aged 12 and older.
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Israel: health.gov.il.